RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-11.75%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$1.72B
AUM Growth
+$1.72B
(-8.2%)
Cap. Flow
+$165M
Cap. Flow
% of AUM
9.61%
Top 10 Holdings %
Top 10 Hldgs %
73.79%
Holding
30
New
4
Increased
9
Reduced
2
Closed
5
Top Buys
| 1 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$169M |
| 2 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
$76.2M |
| 3 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
$24.5M |
| 4 |
Moderna
MRNA
|
$23.1M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
$18.4M |
Top Sells
| 1 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
$110M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$49.6M |
| 3 |
PGNX
Progenics Pharmaceuticals Inc
PGNX
|
$19M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$16M |
| 5 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$15.8M |
Sector Composition
| 1 | Healthcare | 95.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Apellis Pharmaceuticals
APLS
$3.48B
| – | – |
-900,000
| Closed | -$16M |
|
|
CBIO
27
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| – | – |
-253,547
| Closed | -$3.65M |
|
|
SAGE
28
DELISTED
Sage Therapeutics
SAGE
| – | – |
-350,933
| Closed | -$49.6M |
|
|
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| – | – |
-3,030,303
| Closed | -$19M |
|
|
ECYT
30
DELISTED
Endocyte, Inc. Common Stock
ECYT
| – | – |
-6,196,143
| Closed | -$110M |
|